Jefferson Chambers, DO
Pulmonary Disease · Salt Lake City, UTNPI 1821470295
Payments from drug & device makers
What this record shows
The money is spread across several categories — grants (52.5%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. 5 manufacturers reported payments, led by Boston Scientific at 52.5% of the total. 2025 is the largest year on record at $24,700, more than ten times the $27 reported in 2019. Among pulmonary disease clinicians in UT with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 77 payments — averaging $742.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$30K
- Intuitive Surgical$26K
- Pinnacle Biologics, Inc$1K
- Pulmonx Corporation$135
- Abbott$114
What the payments were for
- Speaking & faculty fees$10,00018%
- Grants$30,00053%
- Travel & lodging$14,59326%
- Food & beverage$2,5494%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 3 | $30,027 |
| Intuitive Surgical | 66 | $25,668 |
| Pinnacle Biologics, Inc | 5 | $1,199 |
| Pulmonx Corporation | 2 | $135 |
| Abbott | 1 | $114 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GENERAL - BILIARY DEVICES$30,000
- Da Vinci Surgical System$14,082
- DA VINCI SP$10,600
- Photofrin$1,100
- ZEPHYR DELIVERY CATHETER$121
- PULMONX CHARTIS TABLET CONSOLE$121
- ZEPHYR ENDOBRONCHIAL VALVE$121
- CHARTIS CATHETER$121
- NAVITOR$114
How this compares
$57,142 in reported general payments places this provider in the 90th percentile of 101 pulmonary disease providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Incruse ElliptaUmeclidinium Bromide | 13 | $4,307 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 26 | $708 |
| Prednisone | 34 | $90 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Salt Lake City
- Mary ScholandSalt Lake City$325K
- Chakravarthy ReddySalt Lake City$82K
- James PearlSalt Lake City$69K
- Lara HardmanSalt Lake City$37K
- Charles ElliottSalt Lake City$12K
- Jacqueline ChoaSalt Lake City$9K
- Ann JefferdsSalt Lake City$9K
- Erin BlackstockSalt Lake City$7K
- Michael BourneSalt Lake City$6K
- Kurt FrancisSalt Lake City$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.